Subtype
Male Reproductive System Neoplasm
CI-CAN-00001107Explore in graph →
Non-malignant1,533 active trials27 approved drugs58 evidence items
- NCIt
- C3054
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001107Explore in graph →
Clinical trials
6,899 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00271687 | A Pilot Study of Exercise in Patients With Docetaxel-Based Chemotherapy for Hormone Refractory Prostate Cancer | completed | Phase 2 | 30 | AHS Cancer Control AlbertaOTHER | 1 | Feb 25, 2016 | clinicaltrials |
| NCT02014831 | Efficacy and Safety of Cetuximab in Metastatic Penile Carcinoma (PENILANE)(PENILANE) | withdrawn | Phase 2 | 0 | Centre Leon BerardOTHER | 1 | Feb 25, 2016 | clinicaltrials |
| NCT00587964 | Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases | completed | Phase 2 | 51 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 22, 2016 | clinicaltrials |
| NCT02035124 | Cabazitaxel and BKM120 in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel | withdrawn | Phase 2 | 0 | SCRI Development Innovations, LLCOTHER | 1 | Feb 11, 2016 | clinicaltrials |
| NCT00454571 | Pazopanib Hydrochloride After Leuprolide Acetate or Goserelin Acetate in Treating Patients With Relapsed Prostate Cancer | completed | Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Feb 10, 2016 | clinicaltrials |
| NCT00242138 | Erectile Dysfunction/Prostate/RT/Androgen | completed | Phase 2 | 50 | University Health Network, TorontoOTHER | 1 | Feb 9, 2016 | clinicaltrials |
| NCT01206036 | CESAR Study in Prostate Cancer With Temsirolimus Added to Standard Docetaxel Therapy (CEPTAS)(CEPTAS) | completed | Phase 1 / Phase 2 | 19 | Central European Society for Anticancer Drug ResearchOTHER | 1 | Jan 27, 2016 | clinicaltrials |
| NCT00085566 | Everolimus and Gefitinib in Treating Patients With Progressive Glioblastoma Multiforme or Progressive Metastatic Prostate Cancer | completed | Phase 1 / Phase 2 | 61 | Memorial Sloan Kettering Cancer CenterOTHER | 2 | Jan 20, 2016 | clinicaltrials |
| NCT00124566 | Study of Irofulven in Patients With Hormone-refractory Prostate Cancer | completed | Phase 2 | 135 | Eisai Inc.INDUSTRY | 9 | Jan 18, 2016 | clinicaltrials |
| NCT02643511 | Hemiablative Focal Brachytherapy Pilot Study | unknown | Phase 2 | 20 | St George Hospital, AustraliaOTHER | 1 | Dec 31, 2015 | clinicaltrials |
| NCT00734851 | Multimodality Phase II Study in Prostate Cancer | terminated | Phase 2 | 36 | Duke UniversityOTHER | 1 | Dec 23, 2015 | clinicaltrials |
| NCT01674270 | Degarelix Neo-Adjuvant Radical Prostatectomy Trial | completed | Phase 2 | 35 | University Health Network, TorontoOTHER | 1 | Dec 22, 2015 | clinicaltrials |
| NCT01477749 | Sipuleucel-T Manufacturing Demonstration Study | completed | Phase 2 | 47 | DendreonINDUSTRY | 4 | Dec 9, 2015 | clinicaltrials |
| NCT00932672 | Atkins Diet and Prostate Cancer Clinical Trial | terminated | Phase 2 | 45 | Duke UniversityOTHER | 1 | Dec 7, 2015 | clinicaltrials |
| NCT00381836 | Effect of Darbepoetin Alfa (Aranesp®) on Anemia in Patients With Advanced Hormone Independent Prostate Cancer | terminated | Phase 2 / Phase 3 | 140 | University of AarhusOTHER | 1 | Dec 4, 2015 | clinicaltrials |
| NCT00020735 | Toremifene Followed by Radical Prostatectomy in Treating Patients With Stage I or Stage II Prostate Cancer | completed | Phase 2 | 45 | Joel Nelson, MDOTHER | 1 | Dec 2, 2015 | clinicaltrials |
| NCT00110188 | Ridaforolimus (AP23573/MK-8669) in Participants With Taxane-Resistant Androgen-Independent Prostate Cancer (AIPC)(MK-8669-017) | completed | Phase 2 | 39 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Nov 20, 2015 | clinicaltrials |
| NCT00741039 | Prospective Trial of Vaccine Responses Against Pneumococcus and Influenza in Adult Cancer Patients 65 Years of Age and Older | completed | Phase 2 | 126 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 20, 2015 | clinicaltrials |
| NCT00928174 | Measurement of Anti-Androgen Response Using Fluorine-18 Fluorocholine PET/CT in Androgen-Insensitive Prostate Cancer | completed | Phase 1 / Phase 2 | 27 | Queen's Medical CenterOTHER | 1 | Nov 11, 2015 | clinicaltrials |
| NCT01898065 | Evaluation of Hypoxia by PET With F-Miso in Radiation Therapy of Prostate Cancer(HYPOXProstat) | completed | Phase 2 | 20 | Institut Cancerologie de l'OuestOTHER | 1 | Nov 9, 2015 | clinicaltrials |
| NCT01795703 | A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer Who Have Received Docetaxel | completed | Phase 2 | 47 | Janssen Research & Development, LLCINDUSTRY | 1 | Nov 4, 2015 | clinicaltrials |
| NCT00524680 | Vitamin D in Treating Patients With Prostate Cancer | completed | Phase 2 | 148 | Roswell Park Cancer InstituteOTHER | 1 | Nov 2, 2015 | clinicaltrials |
| NCT01541007 | A Study Looking at Novel Scheduling of Cabazitaxel for Patients With Metastatic Prostate Cancer(ConCab) | completed | Phase 2 | 100 | Jeffrey Yachnin M.D., PhD.OTHER | 1 | Nov 2, 2015 | clinicaltrials |
| NCT00853697 | Exogenous Testosterone Plus Dutasteride for the Treatment of Castrate Metastatic Prostate Cancer | completed | Phase 2 | 6 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 30, 2015 | clinicaltrials |
| NCT00453310 | Sunitinib in Treating Patients With Metastatic Germ Cell Tumors That Have Relapsed or Not Responded to Treatment | completed | Phase 2 | 10 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 27, 2015 | clinicaltrials |
| NCT00560482 | Efficacy Study of ABR-215050 to Treat Prostate Cancer | completed | Phase 2 | 206 | Active Biotech ABINDUSTRY | 3 | Oct 26, 2015 | clinicaltrials |
| NCT02042885 | A Clinical Trial to Determine the Most Suitable Dose of OPB-111001 in Patients With Advanced Cancer | terminated | Phase 1 / Phase 2 | 79 | Otsuka Novel Products GmbHINDUSTRY | 1 | Oct 20, 2015 | clinicaltrials |
| NCT01530984 | Ipilimumab and GMCSF Immunotherapy for Prostate Cancer | withdrawn | Phase 2 | 0 | Lawrence FongOTHER | 1 | Oct 5, 2015 | clinicaltrials |
| NCT00585416 | Study of CGC-11047 in Patients With Metastatic Hormone Refractory Prostate Cancer | terminated | Phase 2 | 23 | University of Wisconsin, MadisonOTHER | 1 | Oct 2, 2015 | clinicaltrials |
| NCT02480010 | A Study of Pertuzumab in Participants With Prostate Cancer | terminated | Phase 2 | 68 | Hoffmann-La RocheINDUSTRY | 6 | Sep 18, 2015 | clinicaltrials |
| NCT02338700 | Safety and Efficacy Study of Mix Vaccine in Prostate Carcinoma Patient | completed | Phase 1 / Phase 2 | 20 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 10, 2015 | clinicaltrials |
| NCT00818480 | An Extension Study Administering YM155 to Subjects Previously Enrolled in Another Protocol Administering YM155 | completed | Phase 2 | 10 | Astellas Pharma IncINDUSTRY | 1 | Sep 4, 2015 | clinicaltrials |
| NCT01368003 | STA-9090 in Castration-Resistant Prostate Cancer With Assessment of Androgen Receptor Pathway Signaling | withdrawn | Phase 2 | 0 | Toni Choueiri, MDOTHER | 1 | Sep 1, 2015 | clinicaltrials |
| NCT00777959 | Bicalutamide and Ridaforolimus in Men With Prostate Cancer (MK-8669-002) | completed | Phase 2 | 22 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 19, 2015 | clinicaltrials |
| NCT01897207 | Phase I/II Study of Vaccination With Antigen Loaded Dendritic Cells (DCs) in Hormone-Refractory Prostate Cancer | completed | Phase 1 / Phase 2 | 15 | Cantonal Hospital of St. GallenOTHER | 0 | Aug 17, 2015 | clinicaltrials |
| NCT00514267 | An Open-Label Study of YM155 + Docetaxel in Subjects With Advanced Hormone Refractory Prostate Cancer and Other Solid Tumors | completed | Phase 1 / Phase 2 | 32 | Astellas Pharma IncINDUSTRY | 1 | Aug 13, 2015 | clinicaltrials |
| NCT00817739 | Intermittent Hormonal Therapy With Leuprorelin and Flutamide in the Treatment of Stage D2 or TxNxM1b,c | completed | Phase 2 | 341 | TakedaINDUSTRY | 0 | Jul 29, 2015 | clinicaltrials |
| NCT01561482 | Study of Metformin With Simvastatin for Men With Prostate Carcinoma | withdrawn | Phase 2 | 0 | Nicholas MitsiadesOTHER | 1 | Jul 22, 2015 | clinicaltrials |
| NCT00188799 | Xray Volume Imaging (Cone Beam CT) - Prostate Cancer | completed | Phase 2 | 30 | University Health Network, TorontoOTHER | 1 | Jul 16, 2015 | clinicaltrials |
| NCT00936975 | Fluorine F 18 Sodium Fluoride Positron Emission Tomography in Evaluating Response to Dasatinib in Patients With Prostate Cancer and Bone Metastases | completed | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | Jul 16, 2015 | clinicaltrials |
| NCT01436214 | Dose-Escalation and Safety Study of APC-100 for the Treatment of Prostate Cancer | unknown | Phase 1 / Phase 2 | 60 | Adamis Pharmaceuticals CorporationINDUSTRY | 1 | Jul 16, 2015 | clinicaltrials |
| NCT01808534 | Palifosfamide in Treating Patients With Recurrent Germ Cell Tumors | terminated | Phase 2 | 5 | Indiana UniversityOTHER | 1 | Jul 2, 2015 | clinicaltrials |
| NCT00108732 | A Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With PSA Progression After Local Therapy for Prostate Cancer | completed | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Jun 30, 2015 | clinicaltrials |
| NCT02049190 | Phase 1-2 Study of Onapristone in Patients With Advanced Castration-resistant Prostate Cancer | unknown | Phase 1 / Phase 2 | 75 | Arno TherapeuticsINDUSTRY | 1 | Jun 24, 2015 | clinicaltrials |
| NCT00058539 | Safety and Efficacy Study of Pertuzumab to Treat Castration-Resistant Prostate Cancer | completed | Phase 2 | 42 | Genentech, Inc.INDUSTRY | 0 | Jun 23, 2015 | clinicaltrials |
| NCT01705652 | Study to Assess the Activity of Nexrutine® in Prostate Cancer Patients(Nexrutine) | terminated | Phase 2 | 21 | The University of Texas Health Science Center at San AntonioOTHER | 1 | Jun 11, 2015 | clinicaltrials |
| NCT02424513 | A Study of Positron Emission Tomography (PET) With [89]Zr-Df-IAb2M in Patients With High-risk Prostate Cancer | withdrawn | Phase 2 | 0 | ImaginAb, Inc.INDUSTRY | 1 | Jun 2, 2015 | clinicaltrials |
| NCT00118066 | Calcitriol in Preventing Prostate Cancer in Patients With Prostatic Intraepithelial Neoplasia | terminated | Phase 2 | 12 | Rutgers, The State University of New JerseyOTHER | 1 | May 27, 2015 | clinicaltrials |
| NCT00743379 | Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 71 | Threshold PharmaceuticalsINDUSTRY | 1 | May 7, 2015 | clinicaltrials |
| NCT00715104 | Sipuleucel-T as Neoadjuvant Treatment in Prostate Cancer(NeoACT) | completed | Phase 2 | 42 | DendreonINDUSTRY | 1 | May 4, 2015 | clinicaltrials |
Data updated 23 days agoSource updated Feb 25, 2016source: clinicaltrials